How to Help Your Patients Save Money on Etanercept: A Provider's Guide to Savings Programs

Etanercept (Enbrel) is one of the most effective treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis — and one of the most expensive. With a list price of approximately $8,000–$11,000 per month in the US (and no biosimilar competition until 2029), cost is the single most common reason patients discontinue therapy or cannot initiate it. As a prescriber, knowing how to connect your patients with appropriate financial support programs is as important as knowing the drug's clinical profile.

Why Etanercept Cost Is a Particular Challenge in 2026

Unlike adalimumab (Humira), which now has more than a dozen US biosimilars driving down list prices, etanercept has no commercially available biosimilars in the US. An Amgen manufacturing process patent blocks US biosimilar market entry until 2029. This means:

No price competition from biosimilars for at least 3 more years

Manufacturer assistance programs carry more weight than they do for drugs with biosimilar competition

Patients who lose commercial insurance face a much steeper cost cliff than those on Humira, who can switch to a lower-cost biosimilar

Program 1: Enbrel SupportPlus Copay Card (Commercial Insurance Patients)

The Enbrel SupportPlus copay assistance program is the most impactful savings resource for your commercially insured patients. Key program details:

Benefit: Eligible patients pay as little as $0 per month, with the program covering up to $12,000 per year in copay costs

Eligibility: Must have commercial (private/employer) insurance. Excludes Medicare, Medicaid, and other federal or state government health insurance.

Enrollment: Can be done through your office, the specialty pharmacy, or by the patient directly through the Enbrel SupportPlus website or phone line.

Practice tip: Build copay card enrollment into your new biologic patient workflow. Many practices include the enrollment form in the same packet as the specialty pharmacy referral and prior authorization paperwork.

Program 2: Amgen Safety Net Foundation (Uninsured and Underinsured Patients)

For patients without adequate insurance coverage, the Amgen Safety Net Foundation can provide etanercept at no cost. This program is income-based:

Benefit: Full medication cost coverage for qualifying patients

Eligibility: Income typically at or below 500% of federal poverty level; must lack adequate insurance coverage for etanercept

Application: Submitted through the prescriber's office; requires prescriber signature and patient income documentation

Timeline: Processing typically takes 2-4 weeks. If your patient is currently on therapy, ensure a bridge is in place while the application is reviewed.

Program 3: Medicare-Specific Savings (Part D Patients)

Medicare patients need a different approach since manufacturer copay cards cannot be used with federal programs. Key options for your Medicare patients:

$2,000 Annual OOP Cap: The Medicare Part D out-of-pocket cap (effective 2025 under the IRA) means patients who use high-cost drugs like etanercept reach their limit early in the year. After $2,000 in covered drug costs, Medicare covers all further eligible costs for the rest of the year.

CMS Price Negotiation: Etanercept was selected by CMS for government drug price negotiation under the IRA. The target negotiated price for Medicare is approximately $2,355 per month — a reduction from the current list price, though still significant.

Extra Help / Low Income Subsidy (LIS): Patients with limited income and resources may qualify for Extra Help, which covers most drug costs including copays. In 2025, full LIS enrollees pay no more than $12.15 per fill for brand-name drugs. Screen your Medicare patients for LIS eligibility and refer them to SSA.gov or 1-800-MEDICARE to apply.

Medicare Savings Programs (MSPs): State-run programs that help cover Part B and Part D premiums and copays for low-income Medicare beneficiaries. Eligibility varies by state.

Program 4: Independent Charitable Patient Assistance Organizations

For patients who fall through the gaps — particularly Medicare patients who don't qualify for Extra Help but still face high costs — independent charitable organizations may help:

HealthWell Foundation: Provides financial assistance for specialty drug copays; has specific funds for autoimmune conditions including RA. Check eligibility at healthwellfoundation.org.

Patient Advocate Foundation: Provides copay relief for insured patients with specific diagnoses. patientadvocate.org.

PAN Foundation (Patient Access Network): Disease-specific funds for underinsured patients facing high drug costs. panfoundation.org.

When to Consider Switching to a More Affordable Alternative

Despite all assistance programs, some patients will face ongoing cost barriers with etanercept. In these cases, a clinical conversation about switching to an adalimumab biosimilar may be appropriate. Multiple FDA-approved adalimumab biosimilars are commercially available with significantly lower list prices and strong copay assistance programs. Switching requires:

A new prescription written by the prescriber

A new prior authorization for the new drug (can often cite prior etanercept approval history)

Patient counseling about the similarity of mechanism and expected clinical response

A monitoring visit 8-12 weeks post-switch to verify maintained disease control

Practice Workflow: Proactive Cost Screening

Consider building these touchpoints into your biologic prescribing workflow:

At initiation: Enroll in Enbrel SupportPlus or submit patient assistance application before first fill

At 3-month visit: Check if patient is actually using their copay card and confirm their out-of-pocket is manageable

At annual visit: Verify insurance status hasn't changed; screen for Medicare Extra Help eligibility if applicable

At any visit where patient mentions cost concerns: Refer immediately to Enbrel SupportPlus or assistance programs before the patient skips doses or stops therapy

When patients also face access (not just cost) challenges, medfinder for providers helps your care team direct patients to pharmacies that can actually fill their prescription — a complement to financial assistance programs that addresses the logistics of access. Visit medfinder.com/providers to learn more.

See also: Etanercept shortage: what providers need to know in 2026 — for a complete overview of the access landscape.